Yahoo
NasdaqGS - Nasdaq Real Time Price USD

BlossomHill Therapeutics, Inc. (BLSM)

13.75 -1.46 (-9.60%)
At close: October 30 at 4:00:01 PM EDT
13.75 0.00 (0.00%)
After hours: October 30 at 5:01:38 PM EDT
Chart Range Bar
Loading chart for BLSM
  • Previous Close 15.21
  • Open 16.40
  • Bid 13.70 x 100
  • Ask 13.84 x 100
  • Day's Range 13.51 - 16.40
  • 52 Week Range 12.93 - 27.99
  • Volume 155,794
  • Avg. Volume 226,758
  • Market Cap (intraday) 437.042M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -4.70
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 35.40
  • Zacks Rating Neutral

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

bhtherapeutics.com

69

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BLSM
12.70%
S&P 500 (^GSPC)
10.73%

1-Year Return

BLSM
12.70%
S&P 500 (^GSPC)
11.11%

3-Year Return

BLSM
12.70%
S&P 500 (^GSPC)
81.91%

5-Year Return

BLSM
12.70%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -23.76M
Profit Margin 0.00%

Q2

FY26

-20M
-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

30.00
35.40 Average
13.75 Current
40.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/21/2026
Analyst Leerink Partners
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 36 -> 40

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -81.6M

  • Diluted EPS (ttm)

    -4.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    95.38M

  • Total Debt/Equity (mrq)

    28.49%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: